Skip to content
Back to search

NCT05828446Recruiting

Improving Hepatocellular Carcinoma Screening

Summary

This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs. abbreviated magnetic resonance imaging (AMRI). The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and non-contrast AMRI. Interested and eligible patients will be enrolled and undergo HCC screening rounds including US +/- contrast-enhanced US (clinical routine) and screening MRI within the same week bi-annually.

Inclusion criteria

• All adult patients with chronic liver disease and indication for HCC screening according to the European Association for the Study of the Liver recommendations. • Informed Consent signed by the subject

Exclusion criteria

• History of HCC • History of other malignancy • Prior liver nodule categorized as LI-RAD 4, 5 or M • History of liver transplantation • Pregnancy • MRI or MRI contrast agent precaution • Any other condition making the patient unsuitable for the study • Patient's refusal of transmission of relevant medical conditions found on the medical examinations performed during the study

Contacts

The trial team's contact details are shown on request.

See the official trial record
Status
Recruiting
Phase
No phase (N/A)
Study type
Interventional
Countries
Switzerland
Sponsor
Naik Vietti Violi(Other)
Protocol no.
CER-VD 2022-D0116
Conditions
Magnetic Resonance Imaging, Hepatocellular Carcinoma, Screening, Contrast-enhanced US
Interventions
Device

Treatments studied

  • MRI

Locations · 1

  • Lausanne, SwitzerlandLausanne University HospitalRecruiting at this site

In total, worldwide, the only site listed in the registry is recruiting.

Site status per the ClinicalTrials.gov registry (last update posted: April 3, 2025).

This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.

See also

Other versions

These results are indicative and do not replace medical advice — discuss them with your doctor.